Raymond James assumed coverage of Amgen (AMGN) with a Market Perform rating and no price target The firm believes MariTide’s clinical profile warrants the drug being more of a niche player in the obesity market. A meaningful amount of Amgen’s valuation is for MariTide, which warrants a cautious stance, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen to invest $600M in state-of-the-art center for science and innovation
- Veeva’s Clinical Platform selected by Amgen
- Amgen’s Repatha: Balancing Growth Potential with Long-Term Risks
- Royalty Pharma Stock (RPRX) Rises as it Seals $950M Cancer Royalties Deal with Amgen
- Amgen says FDA broadens the approved use of Repatha